Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

The long-term effects of conventional and atypical antipsychotics in patients with probable Alzheimer's disease.

Lopez OL, Becker JT, Chang YF, Sweet RA, Aizenstein H, Snitz B, Saxton J, McDade E, Kamboh MI, DeKosky ST, Reynolds CF 3rd, Klunk WE.

Am J Psychiatry. 2013 Sep;170(9):1051-8. doi: 10.1176/appi.ajp.2013.12081046.

2.

Psychiatric medication and abnormal behavior as predictors of progression in probable Alzheimer disease.

Lopez OL, Wisniewski SR, Becker JT, Boller F, DeKosky ST.

Arch Neurol. 1999 Oct;56(10):1266-72.

PMID:
10520944
4.

A markov model of the cost effectiveness of olanzapine treatment for agitation and psychosis in Alzheimer's disease.

Kirbach S, Simpson K, Nietert PJ, Mintzer J.

Clin Drug Investig. 2008;28(5):291-303.

PMID:
18407715
5.

Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial.

Sultzer DL, Davis SM, Tariot PN, Dagerman KS, Lebowitz BD, Lyketsos CG, Rosenheck RA, Hsiao JK, Lieberman JA, Schneider LS; CATIE-AD Study Group.

Am J Psychiatry. 2008 Jul;165(7):844-54. doi: 10.1176/appi.ajp.2008.07111779. Epub 2008 Jun 2.

6.

All-cause mortality associated with atypical and conventional antipsychotics among nursing home residents with dementia: a retrospective cohort study.

Liperoti R, Onder G, Landi F, Lapane KL, Mor V, Bernabei R, Gambassi G.

J Clin Psychiatry. 2009 Oct;70(10):1340-7. doi: 10.4088/JCP.08m04597yel.

7.

Predictors of nursing home admission among Alzheimer's disease patients with psychosis and/or agitation.

Miller EA, Schneider LS, Rosenheck RA.

Int Psychogeriatr. 2011 Feb;23(1):44-53. doi: 10.1017/S1041610210000244. Epub 2010 Mar 10.

8.

Challenges in estimating mortality risk from antipsychotics in people with Alzheimer's disease.

Carnahan RM.

Am J Psychiatry. 2014 Feb;171(2):227. doi: 10.1176/appi.ajp.2013.13091231. No abstract available.

PMID:
24500460
9.

Neither atypical nor conventional antipsychotics increase mortality or hospital admissions among elderly patients with dementia: a two-year prospective study.

Raivio MM, Laurila JV, Strandberg TE, Tilvis RS, Pitkälä KH.

Am J Geriatr Psychiatry. 2007 May;15(5):416-24.

PMID:
17463191
10.

Assessment of antipsychotic prescribing in Belgian nursing homes.

Azermai M, Elseviers M, Petrovic M, van Bortel L, Stichele RV.

Int Psychogeriatr. 2011 Oct;23(8):1240-8. doi: 10.1017/S104161021100024X. Epub 2011 Mar 22.

PMID:
21418723
11.

Antipsychotic treatment of psychosis and agitation in the elderly.

Daniel DG.

J Clin Psychiatry. 2000;61 Suppl 14:49-52. Review.

12.

Psychosis of Alzheimer's disease: clinical characteristics and history.

Schneider LS, Dagerman KS.

J Psychiatr Res. 2004 Jan;38(1):105-11. Review.

PMID:
14690773
13.

Risk of death in dual-eligible nursing home residents using typical or atypical antipsychotic agents.

Aparasu RR, Chatterjee S, Mehta S, Chen H.

Med Care. 2012 Nov;50(11):961-9. doi: 10.1097/MLR.0b013e31826ec185.

PMID:
23047786
14.

Risk of pneumonia in elderly nursing home residents using typical versus atypical antipsychotics.

Aparasu RR, Chatterjee S, Chen H.

Ann Pharmacother. 2013 Apr;47(4):464-74. doi: 10.1345/aph.1R510. Epub 2013 Apr 2.

PMID:
23548651
15.

Psychosis, agitation, and antipsychotic treatment in dementia.

Devanand DP.

Am J Psychiatry. 2013 Sep;170(9):957-60. doi: 10.1176/appi.ajp.2013.13060767. No abstract available.

PMID:
24030608
16.

The use of atypical antipsychotics in nursing homes.

Liperoti R, Mor V, Lapane KL, Pedone C, Gambassi G, Bernabei R.

J Clin Psychiatry. 2003 Sep;64(9):1106-12.

PMID:
14628988
17.

The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease.

Ballard C, Waite J.

Cochrane Database Syst Rev. 2006 Jan 25;(1):CD003476. Review.

PMID:
16437455
18.

Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses.

Mintzer JE, Tune LE, Breder CD, Swanink R, Marcus RN, McQuade RD, Forbes A.

Am J Geriatr Psychiatry. 2007 Nov;15(11):918-31.

PMID:
17974864
19.

Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia.

Declercq T, Petrovic M, Azermai M, Vander Stichele R, De Sutter AI, van Driel ML, Christiaens T.

Cochrane Database Syst Rev. 2013 Mar 28;(3):CD007726. doi: 10.1002/14651858.CD007726.pub2. Review.

PMID:
23543555
20.

Supplemental Content

Support Center